Who is sponsoring ChemoSensMM?

ChemoSensMM is sponsored by University of Wuerzburg.

What drugs are being tested in ChemoSensMM?

Interventions: DTIC (dacarbazine), paclitaxel + cisplatin, treosulfan + cytarabine.

What is the status of ChemoSensMM?

ChemoSensMM is currently UNKNOWN.

Last reviewed 2008-10-22 · How we verify

Prospectively Randomized Phase III Study of an Individualized Sensitivity-Directed Combination Chemotherapy Versus DTIC as First-Line Treatment in Stage IV Metastatic Melanoma (ChemoSensMM)

NCT00779714 Phase 3 UNKNOWN

This phase III trial is aimed to investigate the efficacy of an individualized, sensitivity-directed combination chemotherapy in comparison to the standard regimen DTIC. Two question are aimed to be answered by this study: 1. Is the individual chemosensitivity index (BICSI) a prognostic / predictive biomarker for chemotherapy ? 2. Is an individualized, sensitivity-directed combination chemotherapy superior to the standard regimen DTIC in terms of survival and response ?

Details

Lead sponsor	University of Wuerzburg
Phase	Phase 3
Status	UNKNOWN
Enrolment	360
Start date	2008-10
Completion	2013-04

Conditions

Melanoma

Interventions

DTIC (dacarbazine)
paclitaxel + cisplatin
treosulfan + cytarabine

Primary outcomes

Disease-specific overall survival — 4 years

Countries

Germany